RENAAL Primary Composite Endpoint Doubling of Serum Creatinine/ESRD/Death
Months
% with event
p=0.024
Risk Reduction: 16%
P
L
Months
p=0.008
Risk Reduction: 22%
751
692
583
329
52
762
689
554
295
36
P (+ CT)
L (+ CT)
746
612
479
263
36
760
584
431
214
24
P
L
Intention-to-treat analysis
Per-protocol analysis
Data on file, MSD
Diapositiva anterior
Diapositiva siguiente
Ir a la primera diapositiva
Ver versión gráfica